跳至主要内容
临床试验/EUCTR2015-002255-10-GB
EUCTR2015-002255-10-GB进行中(未招募)1 期

INFLAMMATORY RESPONSE IN MAJOR INJURY & RECOMBINANT HUMAN ERYTHROPOIETIN (IRMINE) - A PILOT STUDY - IRMINE pilot

Abertawe Bro Morgannwg University Health Board0 个研究点目标入组 10 人开始时间: 2016年6月21日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
10

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • The patient is eligible to participate in the study if they:
  • have undergone a significant blunt trauma (injury severity score =16)
  • have been admitted to ITU with an expected stay >3 days.
  • are aged between 18-64 years on admission.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range: 0
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 10
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range 0

排除标准

  • The patient will not be eligible to participate in the study if they:
  • Are pregnant (an admission pregnancy test is routine in all female trauma patients who are of child-bearing age).
  • Have a severe isolated traumatic brain injury.
  • Have any blood-borne infections e.g. HIV, hepatitis B or C.
  • Have any known malignancies.
  • Are already participating in another clinical trial.
  • Have a contra-indication to thromboprophylaxis.
  • Have contra-indications for rhEPO:-
  • oUncontrolled hypertension.
  • oKnown sensitivity to mammalian cell derived products.
  • oHypersensitivity to the active substance or to any of the excipients.
  • oPatients who have severe coronary, peripheral arterial, carotid or cerebral vascular disease, including patients with recent myocardial infarction or cerebral vascular accident (within 3 months).
  • oPatients who have developed Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin.
  • oA history of thrombo-embolic vascular events (TVEs).

研究者

发起方
Abertawe Bro Morgannwg University Health Board

相似试验